AIM-HI Accelerator

Deadline - January 13, 2021

A startup’s success depends on many factors and having the right partners in the ecosystem is such an important factor. AIM-HI provides portfolio companies with vetted Contract Research Organizations (CROs) with the specific expertise to conduct intensive iterative aspects of research and development to pharma standards so that there may not be the need for pharma to repeat experiments. As well, AIM-HI will provide regulatory path guidance from our experience working with the FDA and other Government entities.